Honorary Professor Jean-Pierre Levesque is an Honorary Professor at the Mater Research Institute within the Faculty of Health, Medicine and Behavioural Sciences, University of Queensland. He serves as Principal Research Fellow and joint Head of the Cancer Biology and Care Program at Mater Research Institute, leading the Stem Cell Biology Research Group with a team of six researchers. A National Health and Medical Research Council (NHMRC) Fellow, his research focuses on haematopoietic stem cell biology, including bone marrow niches that regulate normal and malignant haematopoiesis, stem cell mobilization and transplantation, macrophages in haematopoiesis and leukemia, heterotopic ossification following spinal cord and brain injuries, inflammatory bowel disease-associated anaemia, acute myeloid leukemia, myeloproliferative neoplasms, oncostatin M signaling, glucocorticoid stress responses, endothelial protein C receptor CD201, E-selectin blockade, and pathogen-associated molecular patterns.

Levesque has obtained over $8 million in competitive grants, including NHMRC Research Fellowships (2018–2022, 2013–2017), Project Grants on endothelial selectins in stem cell fate (2017–2020), recipient bone marrow macrophages in transplantation (2016–2019), hypoxia sensing in mobilization (2014–2016), and IDEAS Grants such as Mechanisms and first prophylactic treatments of neurogenic heterotopic ossifications (2025–2028) and Discovering mechanisms of neurogenic heterotopic ossifications (2020–2024). He has principal-supervised PhD theses including Role of infections and gut microflora in neurogenic heterotopic ossifications (2023), The Role of Macrophages in Acute Myeloid Leukaemia (2021), and Role of Bone Marrow Macrophages in Regulating Haematopoiesis (2015). His contributions include clinical introduction of Plerixafor for stem cell mobilization in multiple myeloma and lymphoma, guidelines in 'How I treat patients who mobilize hematopoietic stem cells poorly' (Blood, 2011), and discoveries of bone marrow niche proteins causing leukemia chemotherapy resistance, leading to preclinical sensitization models and clinical trials with higher AML remission rates. He holds four patents, edits an international haematology journal, and performs NHMRC peer review. Highly cited publications encompass 'Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs' (Blood, 2010), 'Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide' (Journal of Clinical Investigation, 2003), 'Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance' (Nature Medicine, 2012), and 'G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow' (Blood, 2005). Recent articles include 'A glucocorticoid spike derails muscle repair to heterotopic ossification after spinal cord injury' (Cell Reports Medicine, 2024) and 'Role of endocrinal dysregulations in traumatic heterotopic ossification pathogenesis' (Current Opinion in Endocrinology, Diabetes and Obesity, 2025).

Professional Email: jp.levesque@mater.uq.edu.au